Xcout IntelPD Theranostics, Inc.
PD Theranostics, Inc. (operating as United Theranostics) provides molecular imaging and precision radiopharmaceutical therapy for cancer patients, specializing in treatments for prostate cancer, neuroendocrine tumors, and thyroid cancer. The company utilizes advanced diagnostics such as PET and SPECT scans combined with targeted radiopharmaceuticals to deliver personalized, outpatient treatment plans. Additionally, they participate in clinical trials and collaborate with referring providers to offer innovative cancer care options.
Subscribe to see PD Theranostics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
PD Theranostics, Inc. at a glance
PD Theranostics, Inc. is a healthcare company headquartered in United States. Its most recent funding round raised $358,165 in July 2022.
PD Theranostics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $358,165 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
PD Theranostics, Inc. competitors
A few of PD Theranostics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Lantheus is a radiopharmaceutical-focused company that develops diagnostic and therapeutic products, with a focus on oncology, neurology, and cardiology. The company serves patients and healthcare providers by delivering life-changing science to improve medical outcomes.
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Pentixapharm Holding AG is a clinical-stage radiopharmaceutical company that develops first-in-class radiopharmaceutical diagnostics and therapeutics, focusing on CXCR4-targeted compounds. The company serves patients and healthcare providers by advancing drug candidates through clinical trials, including Phase III-ready programs.
Newrite Medical is a developer of targeted therapeutic and diagnostic agents for nuclear medicine applications. The company provides radiopharmaceutical development, isotope production, and radioligand therapy technologies.
ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech company based in Garching bei München, Germany. It develops, produces, and globally supplies targeted radiotherapeutic and diagnostic agents for cancer treatment. The company notably secured a major €255 million investment round to further advance its clinical pipeline.
Telix Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Melbourne, Australia, focused on the development of diagnostic and therapeutic radiopharmaceuticals.
Get PD Theranostics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on PD Theranostics, Inc. in Xcout Intel
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access